Evaxion A/S – Sponsored ADR (NASDAQ:EVAX) Stock Has Average Target Price of $11.00 According to Analysts

Shares of Evaxion A/S – Sponsored ADR (NASDAQ:EVAX) have received a consensus rating of “Moderate Buy” from the six brokerages that are currently covering the firm, Marketbeat reports. One equities research analyst has rated the stock with a sell rating and five have given a buy rating to the company. The average 1-year price objective among brokers that have issued ratings on the stock in the last year is $11.00.

Separately, Weiss Ratings reissued a “sell (d-)” rating on shares of Evaxion A/S in a report on Tuesday, October 6th.

Evaxion A/S Stock Performance

Shares of EVAX stock opened at $3.76 on Friday. The stock has a market capitalization of $33.92 million, a price-to-earnings ratio of -3.11 and a beta of 0.50. Evaxion A/S has a one year low of $2.72 and a one year high of $6.92. The company’s 50-day simple moving average is $3.20 and its 200-day simple moving average is $3.46. The company has a debt-to-equity ratio of 0.69, a quick ratio of 5.06 and a current ratio of 5.06.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the company. Rathbones Group PLC purchased a new stake in shares of Evaxion A/S during the first quarter valued at $170,000. Renaissance Technologies LLC acquired a new position in Evaxion A/S during the first quarter valued at approximately $146,000. Finally, Annis Gardner Whiting Capital Advisors LLC bought a new stake in Evaxion A/S during the 1st quarter valued at approximately $112,000. 11.04% of the stock is owned by institutional investors and hedge funds.

Evaxion A/S Company Profile

Evaxion A/S is a Denmark-based biotechnology company developing artificial intelligence-driven immunotherapies. The company’s technology is designed to identify disease-specific targets, known as antigens, and support the development of personalized treatments that stimulate a patient’s immune system to recognize and attack diseased cells or pathogens.

Evaxion’s research programs have focused primarily on personalized cancer immunotherapies, including EVX-01, as well as vaccines and immunotherapies for infectious diseases caused by bacteria and viruses.